 NEW YORK and LONDON, Dec. 11, 2020 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Nasdaq: AKTX, a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement andor leukotriene systems are implicated, announces new data on the efficacy and safety profile of long-term self-administration of nomacopan for treatment of patients with PNH. 